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Abstract. The purpose of the study was to assess the efficacy of single photon emission computed tomography (SPECT) 
with 199Tl and 99mTc-MIBI in the detection of breast, laryngeal and hypopharyngeal cancers. A total of 220 patients were 
included into the study: 120 patients with breast lesions (100 patients with breast cancer and 20 patients with benign 
breast tumors) and 100 patients with laryngeal/hypopharyngeal diseases (80 patients with laryngeal/hypopharyngeal 
cancer and 20 patients with benign laryngeal/hypopharyngeal lesions). No abnormal 199Tl uptake was seen in all patients 
with benign breast and laryngeal lesions, indicating a 100% specificity of 199Tl SPECT. In the breast cancer patients, the 
increased 199Tl uptake in the breast was visualized in 94.8% patients, 99mTc-MIBI—in 93.4% patients. The increased 199Tl 
uptake in axillary lymph nodes was detected in 60% patients, and 99mTc-MIBI—in 93.1% patients. In patients with 
laryngeal/hypopharyngeal cancer, the sensitivity of SPECT with 199Tl and 99mTc-MIBI was 95%. The 199Tl SPECT 
sensitivity in identification of regional lymph node metastases in the patients with laryngeal/hypopharyngeal cancer was 
75% and the 99mTc-MIBI SPECT sensitivity was 17%. The data obtained showed that SPECT with 199Tl and 99mTc-MIBI 
can be used as one of the additional imaging methods in detection of tumors. 
INTRODUCTION
According to the recent WHO data more than 10 million newly diagnosed cancer cases occur annually in the 
world. In many countries cancer ranks the second most common cause of death following cardiovascular diseases 0. 
Nuclear medicine techniques have the advantage over X-ray or magnetic resonance imaging in terms of higher 
specificity with a similar high sensitivity for cancer detection [1–3]. Moreover, the use of nuclear medicine imaging 
in detection of laryngeal/hypopharyngeal tumors allows prevention of unnecessary diagnostic invasive procedures. 
99mT?-methoxy-isobutyl-isonitrile (99mTc-MIBI) is the most widely used single photon emission computed 
tomography (SPECT) tracer in detecting malignant disease [4, 5]. However, this tracer with a relatively high 
sensitivity has rather a low specificity. Therefore, the search for radiopharmaceuticals characterized by a high 
specificity while maintaining adequate sensitivity is of great importance. 
More than 30 years ago the diagnostic value of 201Tl for detecting malignant tumors was studied. It was shown 
that 201Tl, a biological potassium analogue, accumulated actively in tumors [5]. The findings from animal studies 
demonstrated that 201Tl had higher tumor accumulation compared to other radiopharmaceuticals [6, 7]. However, a 
long half-life (72 hours) of 201Tl limited its widespread use, since there was a risk of increased radiation dose to the 
patient's body and critical organs, especially during re-examinations, for example during chemotherapy. 
It is proposed that 199Tl is a more promising isotope than 201Tl, which is currently used in nuclear medicine. 
Unlike 201Tl, 199Tl has a simpler and cheaper production method. There are many reports on the use of this isotope 
for myocardial perfusion scintigraphy. Cellular uptake mechanism of 199Tl is the same as that of 201Tl. However, 
because of its short half-life (7.4 hours), the radiation dose to the patient's whole body and critical organs is 
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significantly reduced. By using 199?l, the radiation dose to critical organs is 4–15 times lower than that by using 201Tl. 
It allows 199?l scintigraphy to be performed 5 times a year for the same patient [8–11].  
The aim of our study was to evaluate the efficacy of SPECT with 199?l in the detection of breast and 
laryngeal/hypopharyngeal carcinomas. 
MATERIALS AND METHODS 
A total of 220 patients were included into the study. There were 120 women with breast disease. Out of them, 
39 patients with stage T1-4N0-2M0 breast cancer and 20 patients with benign breast lesions were injected with 199Tl, 
and 61 patients with stage T1-4N0-2M0 breast cancer were injected with 99mTc-MIBI. There were 80 patients with 
stage T1-3N0-2M0 laryngeal and hypopharyngeal cancers (including 20 patients with recurrent laryngeal/hypopharyn-
geal cancer) and 20 patients with benign diseases. Out of them, 50 patients were injected with 199Tl and the other 
50 patients were injected with 99mTc-MIBI. None of the patients at the time of the survey showed evidence of distant 
metastasis. 
Besides conventional imaging methods such as computed tomography, ultrasound, fibrolaryngoscopy and biopsy, 
all patients underwent preoperative SPECT with 199?l or 99mTc-MIBI. The patients were subsequently operated on 
and surgical specimens were examined histologically and immunohistochemically. The patients with benign breast 
lesions underwent sectoral resection of the breast with subsequent histological examination. 
Single photon emission computed tomography was performed using a double-head gamma-camera (E.CAM 180, 
Siemens) equipped with parallel high energy collimators for 199?l and parallel low energy collimators for 99mTc-
MIBI. The injection of 199?l at the dose of 260 MBq or 99mTc-MIBI at the dose of 740 MBq was made intravenously. 
In the patients with breast disease the injection was made into the antecubital vein contralaterally to the breast lesion 
or in the pedal vein. The images of the breast were obtained with the patients lying in the supine position with the 
arms raised over the head and with the chest, both breasts, axilla and the myocardium, included into the field of view. 
For obtaining SPECT images in the patients with laryngeal/hypopharyngeal cancer, the patients were also placed in 
a supine position, and the detector’s field of the view encompassed the head and neck region and trachea to the 
bifurcation. A total of 32 projection images were recorded into a 64?64 matrix (30 seconds per projection), without 
a magnification factor. The scan images were analyzed using the manufacturer software (e.soft, Siemens, Germany). 
Three-dimensional images of the chest, sagittal, transverse and coronal sections were obtained. Single photon 
emission computed tomography scans were visually assessed. The images of contralateral areas were compared and 
asymmetrically increased radiotracer uptake was considered pathological. 
RESULTS 
Single photon emission computed tomography revealed no abnormal 199Tl uptake in the chest wall and breasts of 
patients with benign breast lesions. Despite a small group of patients (n = 20), the specificity of SPECT with 199Tl 
was 100%.  
In breast cancer patients, the increased 199Tl uptake was visualized in 37 (94.8%) of the 39 patients. Out of 
6 patients with tumors less than 10 mm 4 showed abnormal radiotracer uptake (Fig. 1). In one case, a large mass 
detected by mammography and ultrasound appeared as a cluster of microcalcifications. Carrying out SPECT with 
99mTc-MIBI revealed abnormal formations in the projection of the mammary glands in 59 (93.4%) out of 61 patients 
(Fig. 2). Tumors greater than 10 mm were detected by 199Tl and 99mTc-MIBI SPECT in 100% of cases. 
It is well known that a secondary infiltrative ductal breast carcinoma can be difficult to diagnose. In our study, 
the accuracy in differentiating malignant from benign breast lesions by SPECT with 199Tl was 100%, as well as with 
99mTc-MIBI (Figs. 3, 4).  
 
 
FIGURE 1. SPECT with 199Tl for the patient with stage T2N0M0 cancer in the left breast 
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FIGURE 2. SPECT with 99mTc-MIBI for the patient with stage T1N0M0 cancer in the left breast 
 
 
FIGURE 3. SPECT with 199Tl for the patient with secondary infiltrative ductal breast carcinoma in the right breast 
 
 
FIGURE 4. SPECT with 99mTc-MIBI for the patient with secondary infiltrative ductal breast carcinoma in the right breast 
 
 
FIGURE 5. SPECT with 199Tl for the patient with multicentric breast cancer in the right breast 
 
Identification of multicentric breast cancer is an important factor in diagnosis of breast cancer. In our study, 
multicentric breast cancer was diagnosed in 66.6% of the patients during the study with 199Tl and in 46.1% with 
99mTc-MIBI (Figs. 5, 6). 
As regard to lymph node involvement, the increased 199Tl uptake in the axillary lymph nodes was observed in 15 
out of 25 patients (60%) with histologically verified metastases (Fig. 7). Only 2 out of 5 patients had abnormal 
radiotracer uptake in the pectoral and subclavicular lymph nodes (Fig. 8). Thus, the 199Tl SPECT sensitivity for the 
detection of metastatic regional lymph nodes in breast cancer patients was 60%. 
It was possible to visualize the modified axillary lymph nodes in almost all the cases during the study with 
99mTc-MIBI: in 27 (93.1%) out of 29 patients with verified metastasis pathological inclusion of the 99mTc-MIBI in 
axillary region was detected (Fig. 9). In addition, pathological changes in the projection of pectoral lymph nodes, 
subclavian and subscapularis groups were detected in 5 patients. This technique allowed us to differentiate between 
different levels of lymph nodes (Fig. 10). The sensitivity of the SPECT with 99mTc-MIBI in identifying metastatic 
regional lymph nodes was 93.1%. The specificity of SPECT with 199Tl was 100%, with 99mTc-MIBI—80%. 
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FIGURE 6. SPECT with 99mTc-MIBI for the patient with multicentric breast cancer in the right breast 
 
 
FIGURE 7. SPECT with 199Tl in the patient with stage T2N1M0 cancer in the left breast. Axillary lymph node visualization 
 
 
FIGURE 8. SPECT with 199Tl in the patient with stage T2N3M0 cancer in the right breast.  
Visualization of pectoral and subclavicular lymph nodes 
 
 
FIGURE 9. SPECT with 99mTc-MIBI in the patient with stage T2N1M0 cancer in the left breast.  
Axillary lymph node visualization 
 
In laryngeal/hypopharyngeal cancer patients, both 199Tl and 99mTc-MIBI abnormal uptake was detected in 95% of 
the patients with primary laryngeal/hypopharyngeal cancer (Figs. 11, 12). It should be noted that despite limitations 
for SPECT in visualization of tumors less than 10 mm. The minimum lesion size was 4 mm in the greatest 
dimension. In 20 out of 20 patients with recurrent laryngeal/hypopharyngeal cancer an abnormal uptake both 199Tl 
and 99mTc-MIBI was detected; it was 100% sensitivity of SPECT with 199Tl and 99mTc-MIBI in the diagnosis of 
recurrent laryngeal/hypopharyngeal cancer. 
The histological examination of specimens obtained by ultrasound-guided fine needle aspiration biopsy showed 
cervical lymph node metastases in 18.3% of cases. On SPECT the lymph nodes, affected by metastases, were 
visualized in the form of tracer hyperfixation focus of irregular shape with rough, indistinct boundaries, expressed 
by a nonuniform distribution of tracer, usually of low intensity.  
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FIGURE 10. SPECT with 99mTc-MIBI in the patient with stage T2N3M0 cancer in the right breast.  
Visualization of pectoral, subclavicular lymph nodes 
 
 
 
FIGURE 11. SPECT with 199?l for the patient with primary laryngeal cancer 
 
 
 
FIGURE 12. SPECT with 99mTc-MIBI for the patient with primary laryngeal cancer 
 
 
 
FIGURE 13. SPECT with 199?l for the patient with primary laryngeal cancer and cervical lymph node metastases 
 
Single photon emission computed tomography with 199Tl could detect biopsy-proven lymph node metastases in 
75% of cases (Fig. 13). When performing SPECT with 99mTc-MIBI we were able to identify the accumulation of the 
drug in the projection of lymph nodes, affected by metastases, in 2 (17%) out of 12 patients (Fig. 14).  
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FIGURE 14. SPECT with 99mTc-MIBI for the patient with primary laryngeal cancer and cervical lymph node metastases 
 
 
 
FIGURE 15. Screens the zones physiological accumulation of 99mTc-MIBI in the projection  
of the thyroid gland and submandibular salivary glands 
 
 
 
FIGURE 16. Physiological accumulation of 199?l 
 
We assume that such a low information content of SPECT with 99mTc-MIBI in the detection of metastases in 
regional lymph nodes is primarily related to their small size and physiological, initially high accumulation of 99mTc-
MIBI in the projection of the thyroid and submandibular salivary glands, which often screens the zones of the 
regional lymph collector (Fig. 15). This effect is less pronounced when using 199Tl (Fig. 16). 
DISCUSSION
Our first experience of using 199?l has clearly indicated that this radiopharmaceutical represents a useful 
diagnostic tool for the detection of breast and laryngel/hypopharyngeal cancers. Single photon emission computed 
tomography with 199?l showed 100% specificity for detecting breast cancer, when compared to 99mTc-MIBI with 
reported specificity varying from 85% to 94% [5, 13]. 
With regard to the assessment of regional lymph node metastasis in patients with laryngeal/hypopharyngeal 
cancer, 199?l SPECT demonstrated high specificity, whereas 99mTc-MIBI failed to evaluate the status of regional 
lymph nodes due to its physiological high uptake in the thyroid gland. 
Despite the abovementioned advantages, 199?l has also disadvantages. This cyclotron-produced radiopharmaceu-
tical has a higher cost compared to 99mTc, the most widely used radioisotope in nuclear medicine. Moreover, our 
findings have demonstrated rather a low sensitivity in the detection of regional lymph node metastases in breast 
cancer patients, thus significantly impairing the diagnostic accuracy. 
Anyway, 199?l is a promising radiopharmaceutical for the detection of malignant tumors; however, further 
studies are required to determine its role in the cancer diagnostic algorithm. 
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